Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Ventas Inc. Common Stock (VTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Ventas Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while Ventas Inc. Common Stock trades at $85.53 (market cap $43.25B). The key difference: Ventas Inc. Common Stock is far larger — about 44.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Ventas Inc. Common Stock pays a 2.47% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Ventas Inc. Common Stock for 6 Days on average.
| MRVI | VTR | |
|---|---|---|
Market Cap | $977.37M | $43.25B |
Volume | 2,742,564 | 3,942,751 |
Sector | Health | Real Estate |
52-Week High | $9.00 | $100.53 |
52-Week Low | $2.83 | $68.89 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $55.97B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Ventas (VTR) trades at $83.85, up 0.37% today, amid a bearish technical signal with resistance near $84. The REIT reported Q2 2026 EPS of $0.14, slightly missing expectations, but maintains strong revenue growth with 2026 guidance at $6.4B. Analyst sentiment is positive with a $99.14 consensus target, supported by demographic tailwinds in senior housing.
The outlook for VTR is cautiously optimistic, driven by aging population trends boosting demand for senior housing. Risks include high valuation multiples and negative cash flow from aggressive investing. Wall Street's buy ratings (56%) suggest confidence in long-term growth, but investors should monitor earnings consistency and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Ventas Inc. Common Stock
Ventas is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, medical office buildings, and research-related facilities.
Read more on VTR →
